Jorge Barboza-Sosa, MD
Internal Medicine · Eagle Pass, TXNPI 1437203437
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AstraZeneca at 39.1% of the total. 2025 is the largest year on record at $648, 2.1 times the $306 reported in 2019.
Across 159 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$810
- Johnson & Johnson$298
- Lilly USA, LLC$168
- Novartis$160
- Amarin Pharma, Inc.$146
- plus $420 from 11 others
What the payments were for
- Food & beverage$3,289100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 58 | $1,288 |
| Novo Nordisk | 38 | $810 |
| Johnson & Johnson | 19 | $298 |
| Lilly USA, LLC | 4 | $168 |
| Novartis | 8 | $160 |
| Amarin Pharma, Inc. | 9 | $146 |
| Merck | 7 | $119 |
| E.r. Squibb & Sons, L.L.C. | 6 | $110 |
| Pfizer | 2 | $38 |
| AbbVie | 1 | $36 |
| Corium, LLC | 1 | $23 |
| Biogen | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Amgen | 1 | $17 |
| Exact Sciences | 1 | $13 |
| Abbott | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$3,289 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 297 | $281,636 |
| LinzessLinaclotide | 125 | $147,903 |
| EliquisApixaban | 125 | $137,619 |
| RybelsusSemaglutide | 69 | $132,887 |
| OzempicSemaglutide | 80 | $94,477 |
| FarxigaDapagliflozin Propanediol | 83 | $93,029 |
| XifaxanRifaximin | 38 | $78,755 |
| XareltoRivaroxaban | 108 | $73,215 |
| JardianceEmpagliflozin | 38 | $62,554 |
| JanumetSitagliptin Phos/Metformin Hcl | 54 | $60,234 |
| TradjentaLinagliptin | 57 | $51,384 |
| MyrbetriqMirabegron | 67 | $35,403 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $31,268 |
| EntrestoSacubitril/Valsartan | 16 | $28,301 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $22,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Janumet Xr | $119 | $373,138372 claims |
| Novo NordiskRybelsus, Ozempic | $810 | $227,364149 claims |
| AbbVieLinzess, Lumigan | $36 | $151,897139 claims |
| PfizerEliquis | $38 | $137,619125 claims |
| AstraZenecaFarxiga, Symbicort | $1,288 | $97,03096 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $12 | $78,75538 claims |
| Johnson & JohnsonXarelto | $298 | $73,215108 claims |
| NovartisEntresto | $160 | $28,30116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Eagle Pass
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.